Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
IL6 3569 SILTUXIMAB CHEMBL1743070 antagonist, inhibitor, antibody MyCancerGenome, ChemblInteractions, DrugBank 8823310
IL6 3569 INTERFERON ALFA-2B CHEMBL1201558 NCI 10022737
IL6 3569 OLOKIZUMAB CHEMBL1743050 inhibitor ChemblInteractions
IL6 3569 CLAZAKIZUMAB CHEMBL2108589 inhibitor TdgClinicalTrial, ChemblInteractions
IL6 3569 IBUDILAST CHEMBL19449 inhibitor DrugBank, TTD
IL6 3569 VX-702 CHEMBL1090090 DrugBank
IL6 3569 GEMFIBROZIL CHEMBL457 NCI 8941582
IL6 3569 NELFINAVIR CHEMBL584 NCI 15388451
IL6 3569 SAQUINAVIR CHEMBL114 NCI 15388451
IL6 3569 CDP-6038 CHEMBL2109652 TdgClinicalTrial
IL6 3569 MIDOSTAURIN CHEMBL608533 NCI 10463595
IL6 3569 ELSILIMOMAB CHEMBL2108591 inhibitor ChemblInteractions
IL6 3569 SIRUKUMAB CHEMBL1743071 inhibitor ChemblInteractions
IL6 3569 PF-04236921 CHEMBL2109613 inhibitor ChemblInteractions
IL6 3569 GINSENG, ASIAN CHEMBL2108467 antagonist DrugBank 17436372, 14642426
IL6 3569 FENTANYL CHEMBL596 NCI 9527747
IL6 3569 IFOSFAMIDE CHEMBL1024 NCI 9260581
IL6 3569 VITAMIN K CHEMBL1201519 NCI 12053098
IL6 3569 ARSENIC TRIOXIDE CHEMBL1200978 NCI 16638192
IL6 3569 LEVOFLOXACIN CHEMBL33 NCI 12714806
IL6 3569 DIHYDROSPINGOSINE CHEMBL448741 NCI 10022508
IL6 3569 GALLIUM NITRATE CHEMBL1200983 NCI 8788232
IL6 3569 LINEZOLID CHEMBL126 NCI 14561977
IL6 3569 METRONIDAZOLE CHEMBL137 NCI 12111578

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
IL6 rs1800795 G adalimumab efficacy yes Allele G is associated with increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to allele C. 24253594 1183699283
IL6 rs1800795 G peginterferon alfa-2a efficacy yes This association is as part of a haplotype which also includes rs1800797G and rs1800796G. This is a GC SNP so the listed associated allele may be incorrect. Allele G is associated with decreased response to peginterferon alfa-2a in people with Hepatitis C, Chronic as compared to allele C. 19387461 981861811
IL6 rs1800795 G Tumor necrosis factor alpha efficacy yes Obesity and the minus174G/C IL-6 gene promoter polymorphism predicted poor response to anti-TNF-a therapies [odds ratio for C(minus) carriers, obese: 2.00 confidence interval: 1.19 to 3.38; P=0.05]. Allele G is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to allele C. 22158445 827815479
IL6 rs1800797 G peginterferon alfa-2a efficacy yes This association is as part of a haplotype which also includes rs1800796G and rs1800795G. Allele G is associated with decreased response to peginterferon alfa-2a in people with Hepatitis C, Chronic as compared to allele A. 19387461 981861796
IL6 rs1800795 CC + CG fenofibrate efficacy yes Carriers of the C allele had a greater reduction in levels of interleukin-6 (IL-6; units = pg/ml) following 30 days of treatment, compared to those with the GG genotype. Genotypes CC + CG are associated with increased response to fenofibrate in patients with a high risk of cardiovascular disease as compared to genotype GG. 16607077 982035499
IL6 rs10499563 CC + CT Tumor necrosis factor alpha efficacy yes Cohort with inflammatory bowel disease (IBD). Subcohorts with Crohn's disease (CD) and ulcerative colitis (UC) were also analyzed. Significant results for this genotype seen for IBD and UC cohorts. Treatment efficacy was defined using the three-step scale (failure, response, or remission) and reflected the maximum response within 22 weeks after treatment initiation. Genotypes CC + CT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative and Inflammatory Bowel Diseases as compared to genotype TT. 24776844 1296666874
IL6 rs1800796 G peginterferon alfa-2a efficacy yes This association is as part of a haplotype which also includes rs1800797G and rs1800795G. This is a GC SNP so the listed associated allele may be incorrect. Allele G is associated with decreased response to peginterferon alfa-2a in people with Hepatitis C, Chronic as compared to allele C. 19387461 981861804
IL6 rs2066992 GT duloxetine efficacy no However, results were not significant after correction for multiple testing. Genotype GT is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to genotype GG. 26556688 1447674916
IL6 rs1524107 C tacrolimus metabolism/PK no This study was attempting to validate reported variants and tacrolimus trough concentration in a large population of African American and European American kidney transplant patients. Authors described association as suggestive in the EA population but it did not survive multiple testing correction. Direction of effect not stated. This is a proxy for rs1800796. Allele C is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation. 29318894 1449162909
IL6 rs10242595 AA duloxetine efficacy no However, results were not significant after correction for multiple testing. Genotype AA is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to genotypes AG + GG. 26556688 1447674939